Traders Unite!

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPLK, NERV and TRIT

The MarketWatch News Department was not involved in the creation of this content.

January 14, 2021 (ACCESSWIRE via COMTEX) — NEW YORK, NY / ACCESSWIRE / January 14, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Splunk Inc. (NASDAQ:SPLK)

Class Period: October 21, 2020 – December 2, 2020

Lead Plaintiff Deadline: February 2, 2021

The SPLK lawsuit alleges that throughout the class period, Splunk Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SPLK: http://www.kleinstocklaw.com/pslra-1/splunk-inc-loss-submission-form?id=12164&from=1

Minerva Neurosciences, Inc. (NASDAQ:NERV)

Class Period: May 15, 2017 – November 30, 2020

Lead Plaintiff Deadline: February 8, 2021

The NERV lawsuit alleges Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company’s plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=12164&from=1

Triterras, Inc., f/k/a Netfin Acquisition Corp. (NASDAQ:TRIT)

Class Period: August 20, 2020 – December 16, 2020

Lead Plaintiff Deadline: February 19, 2021

Triterras, Inc., f/k/a Netfin Acquisition Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the extent to which Company’s revenue growth relied on Triterras’ relationship with Rhodium to refer users to the Kratos platform; (2) that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; (3) that, as a result, Rhodium was likely to refer fewer users to the Company’s Kratos platform; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in TRIT: http://www.kleinstocklaw.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?id=12164&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

Image: https://www.accesswire.com/users/newswire/images/623594/image-20210108102930-1.png

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com:

https://www.accesswire.com/624310/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-SPLK-NERV-and-TRIT

COMTEX_377666525/2457/2021-01-14T08:45:21

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2021 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.

Comments are closed.